Pfizer and its German partner BioNTech are, like other Covid-19 vaccine manufacturers such as AstraZeneca, struggling to meet the huge demand for shots that are the world’s best bet for overcoming the pandemic.
Last month, Sanofi and Britain’s GlaxoSmithKline said a Covid-19 vaccine they are jointly developing had showed an insufficient immune response in older people, delaying its launch to late this year.
“Since our main vaccine is a few months late, we asked ourselves how we could be of assistance now,” Hudson was quoted as saying.
Sanofi is also working on another Covid-19 vaccine candidate with U.S. firm Translate Bio which uses mRNA technology, similar to the approach of Pfizer/BioNTech. Phase I trials are expected to start this quarter.
Hudson confirmed in the interview that Sanofi remains committed to its two vaccines projects.
Read More: Covid vaccine: Sanofi to help produce 100 million Pfizer/BioNTech vaccine